The European Centre for Disease Prevention and Control (ECDC) has published a report today highlighting the threat of increasing antimicrobial resistance (AMR) in Neisseria gonorrhoeae.
The ECDC updates are based on available data reported through the European Surveillance System (TESSy) by the national public health authorities of EU/EEA countries.
ECDC is following reports from several European Union and European Economic Area (EU/EEA) countries of substantial increases in the detection of parvovirus B19 (B19V).
This framework describes the building blocks being laid down by the European Centre for Disease Prevention and Control (ECDC) to support and empower European Union (EU)/European Economic Area (EEA) countries and the European Commission in achieving microbial safety for substances of human origin (SoHO).
ECDC is monitoring reports from three countries (France, the United Kingdom and the United States) of cases of invasive meningococcal disease (IMD) associated with travel to the Kingdom of Saudi Arabia (KSA).
This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
This report describes the external quality assessment (EQA) scheme for the European Legionnaires’ disease Surveillance network, for the detection, isolation, identification, and enumeration of Legionella species.
This report collects all COVID-19 long-term care facilities (LTCF) data reported to ECDC from 2021 and concludes the EU/EEA LTCF COVID-19 specific surveillance data collection from 2021-2023.
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].